Released Aug 9, 2017, after the close
10-Q filed Aug 9, 2017, 40 days after period end · 0001144204-17-041693
Q2 2017 · 10-Q
Revenue$6.36M$6.36M +259.4% vs Q2 2016+120.1% vs Q1 2017
Net Income$450.00K$450.00K N/M vs Q2 2016N/M vs Q1 2017
EPS Diluted-$0.06-$0.06 N/M vs Q2 2016N/M vs Q1 2017
Gross Profit$835,000+788.3%
Operating Income-$10,805,000N/M
Operating Cash Flowderived-$8,619,000N/M
Free Cash Flowderived-$8,942,000N/M
Margins · derived
Gross margin13.1%+7.8 pt vs Q2 2016
Operating margin-169.9%+391.4 pt vs Q2 2016
Net margin7.1%+620.6 pt vs Q2 2016
What the release said
No earnings release is on file for this quarter. Its figures came with the 10-Q.
Same quarter
| Metric | Q2 2017 | Q2 2016 | Q2 2015 | Q2 2014 |
|---|---|---|---|---|
| Revenue | $6.36M | $1.77M | $1.34M | $2.43M |
| Net Income | $450.00K | -$10.85M | -$5.07M | -$6.12M |
| EPS Diluted | -$0.06 | -$0.11 | -$0.05 | -$0.07 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Protalix BioTherapeutics, Inc. · CIK 1006281 · Engraved from SEC EDGAR